External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ESMO IO 2023
Roche and Genentech at

ESMO IO 2023

December 06 - December 08
Geneva, Switzerland / Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
11:00 AM
Duration 1hr Geneva, Switzerland
Krascendo-170 Lung: a phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Skoulidis F, Cuppens K, Sacher A, Velcheti V, Lee D-H, Lin MT, Fernando TM, Li S, Bradley D, Zarak Crnkovic M, Mathisen M
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.